(Reuters) - U.S. drugmaker Regeneron Pharmaceuticals Inc missed Wall Street estimates for first-quarter profit on Thursday due to softer sales of its blockbuster eye drug Eylea and its eczema treatment, Dupixent.

Excluding items, the company reported a profit of $9.55 per share for the quarter, compared with analysts' estimates of $10.09 per share, according to LSEG data.

(Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber)